Development of Functional Nanomedicines for Tumor Associated Macrophages-focused Cancer Immunotherapy

Overview

Journal Theranostics

Date 2022 Dec 1

PMID 36451865

Authors

Xiao Wei

Jing Wang

Min Liang

Mingzhu Song

Affiliations

Soon will be listed here.

Abstract

Clinical cancer immunotherapies are usually impeded by tumor immunosuppression driven by tumor associated macrophages (TAMs). Thus, TAMs can be considered as a promising therapeutic target for improved immunotherapy, and TAMs-focused molecular targeting agents have made ideal progress in clinical practice. Even so, most TAMs-targeting agents still cannot cover up their own shortcomings as free drugs. The emergence of multifunctional nanomaterials can expectedly endow these therapeutic cargoes with high solubility, favorable pharmacokinetic distribution, cell-specific delivery, and controlled release. Here, the underlying mechanisms of tumor immunosuppression caused by TAMs are first emphatically elucidated, and then the basic design of TAMs-focused immune-nanomedicines are discussed, mainly including diverse categories of nanomaterials, targeted and stimulus-responsive modifications, and TAM imaging in nanomedicines. A summary of current TAMs-targeting immunotherapeutic mechanisms based on functional nanomedicines for TAMs elimination and/or repolarization is further presented. Lastly, some severe challenges related to functional nanomedicines for TAMs-focused cancer immunotherapy are proposed, and some feasible perspectives on clinical translation of TAMs-associated anticancer immunonanomedicines are provided. It is hoped that, with rapid development of nanomedicine in cancer immunotherapy, TAMs-focused therapeutic strategies may be anticipated to become an emerging immunotherapeutic modality for future clinical cancer treatment.

Citing Articles

Nanotherapeutics for Macrophage Network Modulation in Tumor Microenvironments: Targets and Tools.

Li R, Huang J, Wei Y, Wang Y, Lu C, Liu J Int J Nanomedicine. 2024; 19:13615-13651.

PMID: 39717515 PMC: 11665441. DOI: 10.2147/IJN.S491573.

Analysis of Lymphovascular Infiltration and Tumor-Associated Macrophages in Cervical Cancer Immunoescape.

Guan L, Xu X, Xu J, Xu G, Zhang Y, Xia H Onco Targets Ther. 2024; 17:1117-1136.

PMID: 39583248 PMC: 11585989. DOI: 10.2147/OTT.S468484.

Polypeptides-Based Nanocarriers in Tumor Therapy.

You J, Guo Y, Dong Z Pharmaceutics. 2024; 16(9).

PMID: 39339228 PMC: 11435007. DOI: 10.3390/pharmaceutics16091192.

Advances in nephroprotection: the therapeutic role of selenium, silver, and gold nanoparticles in renal health.

Karunakar K, Edwin E, Gopalakrishnan M, Cheriyan B, Ramaiyan V, Karthikha V Int Urol Nephrol. 2024; 57(2):479-510.

PMID: 39312019 DOI: 10.1007/s11255-024-04212-4.

Targeting tumor-associated macrophages with nanocarrier-based treatment for breast cancer: A step toward developing innovative anti-cancer therapeutics.

Muteeb G, Khafaga D, El-Morsy M, Farhan M, Aatif M, Hosney M Heliyon. 2024; 10(18):e37217.

PMID: 39309874 PMC: 11415663. DOI: 10.1016/j.heliyon.2024.e37217.

References

Ding J, Zhao D, Hu Y, Liu M, Liao X, Zhao B . Terminating the renewal of tumor-associated macrophages: A sialic acid-based targeted delivery strategy for cancer immunotherapy. Int J Pharm. 2019; 571:118706. DOI: 10.1016/j.ijpharm.2019.118706. View

Chen C, Jing W, Chen Y, Wang G, Abdalla M, Gao L . Intracavity generation of glioma stem cell-specific CAR macrophages primes locoregional immunity for postoperative glioblastoma therapy. Sci Transl Med. 2022; 14(656):eabn1128. DOI: 10.1126/scitranslmed.abn1128. View

Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H . In situ sprayed bioresponsive immunotherapeutic gel for post-surgical cancer treatment. Nat Nanotechnol. 2018; 14(1):89-97. DOI: 10.1038/s41565-018-0319-4. View

Heys S, Stewart K, McKenzie E, Miller I, Wong S, Sellar G . Characterisation of tumour-infiltrating macrophages: impact on response and survival in patients receiving primary chemotherapy for breast cancer. Breast Cancer Res Treat. 2012; 135(2):539-48. DOI: 10.1007/s10549-012-2190-6. View

Elder M, Webster S, Williams D, Gaston J, Goodall J . TSLP production by dendritic cells is modulated by IL-1β and components of the endoplasmic reticulum stress response. Eur J Immunol. 2015; 46(2):455-63. PMC: 4783504. DOI: 10.1002/eji.201545537. View

Lei P, An R, Yao S, Wang Q, Dong L, Xu X . Ultrafast Synthesis of Novel Hexagonal Phase NaBiF Upconversion Nanoparticles at Room Temperature. Adv Mater. 2017; 29(22). DOI: 10.1002/adma.201700505. View

Guo P, Wang L, Shang W, Chen J, Chen Z, Xiong F . Intravesical Immunostimulatory Gel for Triple Therapy of Bladder Cancer. ACS Appl Mater Interfaces. 2020; 12(49):54367-54377. DOI: 10.1021/acsami.0c15176. View

Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G . Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2007; 8(1):59-73. DOI: 10.1038/nri2216. View

Andon F, Digifico E, Maeda A, Erreni M, Mantovani A, Alonso M . Targeting tumor associated macrophages: The new challenge for nanomedicine. Semin Immunol. 2017; 34:103-113. DOI: 10.1016/j.smim.2017.09.004. View

10.

Cao Y, Ding S, Zeng L, Miao J, Wang K, Chen G . Reeducating Tumor-Associated Macrophages Using CpG@Au Nanocomposites to Modulate Immunosuppressive Microenvironment for Improved Radio-Immunotherapy. ACS Appl Mater Interfaces. 2021; 13(45):53504-53518. DOI: 10.1021/acsami.1c07626. View

11.

Deng G, Sun Z, Li S, Peng X, Li W, Zhou L . Cell-Membrane Immunotherapy Based on Natural Killer Cell Membrane Coated Nanoparticles for the Effective Inhibition of Primary and Abscopal Tumor Growth. ACS Nano. 2018; 12(12):12096-12108. DOI: 10.1021/acsnano.8b05292. View

12.

Beatty G, Chiorean E, Fishman M, Saboury B, Teitelbaum U, Sun W . CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011; 331(6024):1612-6. PMC: 3406187. DOI: 10.1126/science.1198443. View

13.

Bobo D, Robinson K, Islam J, Thurecht K, Corrie S . Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharm Res. 2016; 33(10):2373-87. DOI: 10.1007/s11095-016-1958-5. View

14.

Wang Y, Yu J, Luo Z, Shi Q, Liu G, Wu F . Engineering Endogenous Tumor-Associated Macrophage-Targeted Biomimetic Nano-RBC to Reprogram Tumor Immunosuppressive Microenvironment for Enhanced Chemo-Immunotherapy. Adv Mater. 2021; 33(39):e2103497. DOI: 10.1002/adma.202103497. View

15.

Wang Y, Guo G, Feng Y, Long H, Ma D, Leung C . A tumour microenvironment-responsive polymeric complex for targeted depletion of tumour-associated macrophages (TAMs). J Mater Chem B. 2020; 5(35):7307-7318. DOI: 10.1039/c7tb01495c. View

16.

Shan H, Dou W, Zhang Y, Qi M . Targeted ferritin nanoparticle encapsulating CpG oligodeoxynucleotides induces tumor-associated macrophage M2 phenotype polarization into M1 phenotype and inhibits tumor growth. Nanoscale. 2020; 12(43):22268-22280. DOI: 10.1039/d0nr04520a. View

17.

Li H, Du J, Liu J, Du X, Shen S, Zhu Y . Smart Superstructures with Ultrahigh pH-Sensitivity for Targeting Acidic Tumor Microenvironment: Instantaneous Size Switching and Improved Tumor Penetration. ACS Nano. 2016; 10(7):6753-61. DOI: 10.1021/acsnano.6b02326. View

18.

Nathan C, Cunningham-Bussel A . Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nat Rev Immunol. 2013; 13(5):349-61. PMC: 4250048. DOI: 10.1038/nri3423. View

19.

Castro F, Pinto M, Silva A, Pereira C, Teixeira G, Gomez-Lazaro M . Pro-inflammatory chitosan/poly(γ-glutamic acid) nanoparticles modulate human antigen-presenting cells phenotype and revert their pro-invasive capacity. Acta Biomater. 2017; 63:96-109. DOI: 10.1016/j.actbio.2017.09.016. View

20.

Wei B, Pan J, Yuan R, Shao B, Wang Y, Guo X . Polarization of Tumor-Associated Macrophages by Nanoparticle-Loaded Combined with Immunogenic Cell Death for Cancer Immunotherapy. Nano Lett. 2021; 21(10):4231-4240. DOI: 10.1021/acs.nanolett.1c00209. View